CRISPR Therapeutics (CRSP) General Counsel R. Sells $51K of Stock

CRISPR Therapeutics AG's General Counsel, James R. Kasinger, sold 1,040 shares on October 14, 2026, for about $51,230. This transaction comes as the company prepares for its next earnings report on November 9, 2026.

Inside Kasinger's Trade

Kasinger sold the shares at a price of $49.26 each. This sale was not pre-arranged under a Rule 10b5-1 plan. The stock closed at a recent price of $50.98 on October 16, 2026, which is below its 50-day moving average of $54.99 and its 200-day average of $53.13.

Other Institutional Activity in CRISPR Therapeutics

Several institutional investors have adjusted their positions in CRISPR Therapeutics recently. BlackRock Inc. increased its holdings by 668,932 shares, totaling 8,348,977 shares valued at about $411.2 million. Meanwhile, ARK Investment Management reduced its stake by 1,853,267 shares, ending with 9,460,939 shares worth approximately $466.0 million. Orbis Allan Gray Ltd decreased its position by 657,026 shares, bringing its total to 5,449,161 shares valued at about $268.4 million.

CRISPR Therapeutics AG Stock Down 1.0%

CRISPR Therapeutics shares are currently trading around $50.98, which is about 7.3% below the 50-day moving average. The stock is also 32.1% below its 52-week high of $75.06, indicating it may be facing pressure in the market. The stock's target mean price stands at $85.63, suggesting significant upside potential from its recent trading levels.

Recent Earnings

For the trailing twelve months, CRISPR Therapeutics reported revenue of approximately $13.39 million. The company has seen impressive revenue growth of 1,041.4% year-over-year, although it has not generated a profit, with an earnings per share (EPS) of -$4.74. The next earnings report is scheduled for November 9, 2026.

Insider Buying and Selling at CRISPR Therapeutics AG

Kasinger's recent sale follows other insider transactions. On October 6, 2026, he sold an additional 1,990 shares at about $60.04 each. Earlier, on September 22, he sold 10,400 shares at $60.24 each. Other insiders, such as Director Ali Behbahani, also sold shares recently.

Analysts Set New Price Targets

Analysts remain optimistic about CRISPR Therapeutics, with firms like Citigroup maintaining a Buy rating and raising its price target to $88.00 on August 4, 2026. HC Wainwright & Co. also reiterated a Buy rating with a target of $80.00, signaling confidence in the company's future performance. The consensus rating remains a Buy, with a target mean price of $85.63 based on 19 analyst opinions.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland. It focuses on developing innovative gene-based medicines for serious diseases using its CRISPR/Cas9 gene-editing platform. As the company approaches its upcoming earnings date, Kasinger's recent share sale adds to the narrative surrounding its stock performance.

Bottom Line

Investors will be looking closely at CRISPR Therapeutics as it prepares for its earnings report on November 9, 2026. With Kasinger's recent sale and the stock trading below its moving averages, market reactions could be significant. Analysts continue to express optimism, underscoring the potential for recovery in the stock's valuation.